Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Priority to CU20110054ApriorityCriticalpatent/CU20110054A7/en
Publication of CU20110054A7publicationCriticalpatent/CU20110054A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención proporciona compuestos de Fórmula (1A) ESPACIO PARA LA FÓRMULA que actúan como activadores de glucoquinasa; composiciones farmacéuticas de los mismos; y métodos para tratar enfermedades, trastornos o afecciones mediadas por glucoquinasa. X, Y, Z, R1, R2, R3 y R4 son como se han descrito en la presente memoria.The present invention provides compounds of Formula (1A) FORMULA SPACE that act as glucokinase activators; pharmaceutical compositions thereof; and methods for treating diseases, disorders or conditions mediated by glucokinase. X, Y, Z, R1, R2, R3 and R4 are as described herein.
CU20110054A2011-03-112011-03-11
HETEROARIL AMIDA DERIVATIVES AND THEIR USES AS GLUCOQUINASE ACTIVATORS
CU20110054A7
(en)
DERIVATIVES OF DIARIL AND ARILHETEROARIL UREA AS MODULATORS OF THE SEROTONINE 5HT2A RECEPTOR USEFUL FOR PROFILAXIS AND THE TREATMENT OF A DREAM SLEEP BEHAVIORAL DISORDER.
Compounds derived from (phenyl or pyridin) -ethynyl- (pyridin or pyrimidin) substituted; pharmaceutical composition comprising them; process of preparing this; and its use in the treatment of schizophrenia or cognitive diseases.